Introduction
============

Array CGH (aCGH) has shown itself to be a mature technology capable of detecting genomic gains and losses at a resolution of at least 250 base pairs. Clearly at this resolution there will be masses of data that will challenge the analyst, particularly in the light of the general variance of the genome from individual to individual---so called copy number variations (CNV) and knowledge that the function of a substantial part of the genome is still unknown hence referred to as 'orphan' or 'predicted'. It is also clear that genomic copy number aberrations (CNA) associated with diseased cells are likely to interfere with transcriptional pathways and affect gene function.

Significance Analysis of Microarrays (SAM) was developed by Tusher[@b1-cin-11-2012-173] as a straightforward way of comparing data sets using an internally generated false discovery rate (FDR) as the criterion for the identification of probes that significantly differ between 2 or more classes. It has been successfully used to analyse gene expression data and is now routinely applied.[@b2-cin-11-2012-173],[@b3-cin-11-2012-173]

Philadelphia positive malignant disorders are a clinically divergent group of leukaemias with a unique identifying feature, the BCR/ABL1 fusion gene, usually resulting from the chromosome rearrangement t(9;22)(q34;q11) or its variants, that leads to constitutive expression of an aberrant tyrosine kinase. These include chronic myeloid leukaemia (CML) and de novo acute leukaemia of both myeloid Ph(+)AML and lymphoid origin Ph(+)ALL. The latter two disorders are clinically aggressive and therapy challenging even in the era of the powerful tyrosine kinase inhibitors. CML is a multistage progressive disorder which if untreated inevitably ends as fatal acute myeloid or lymphoid blast transformation. The latter, from which it has been reported to differ karyotypically, is usually clinically indistinguishable from Ph(+)ALL the most common type of ALL in adults.[@b4-cin-11-2012-173] Although non-random chromosome changes may accompany disease progression in CML, the genetic background of the malignant transformation from the benign chronic phase (CP) to acute leukaemia (blast crisis, BC) is poorly understood. Recent whole genome screening identified a spectrum of cryptic aberrations associated with disease progression[@b5-cin-11-2012-173],[@b6-cin-11-2012-173] sometimes even present at the onset of CML.[@b7-cin-11-2012-173] Also similar investigations of Ph(+)ALL in both children and adults identified recurrent cryptic loss of *Ikaros*, required for the normal B cell maturation[@b8-cin-11-2012-173] in addition to the known deletions of the *p*16 *(CDKN2A)* gene.

These findings led us to look in CML and Ph(+) ALL for imbalances in DNA sequences significantly associated with the disease stage and lineage origin. We used array CGH data obtained from 40 anonymous bone marrow samples comprising 10 CML chronic phase, 10 CML lymphoid blast phase, 10 CML myeloid blast phase, 10 Ph(+)ALL from the UKALLXII(R) trial \[9\] and 10 peripheral blood samples from disease free individuals. Of the ALL samples 5 had t(9;22)(q34;q11) as a sole cytogenetic abnormality, one was Ph negative but BCR/ABL positive, 3 showed hyperdiploid karyotype (HEH) but none showed aberrations detectable by G banding in the short arm regions of chromosome 7 and 9 ([Table 1](#t1-cin-11-2012-173){ref-type="table"}). The presence of the *BCR*/*ABL1* fusion gene was confirmed in all samples by qPCR and/or FISH (D-FISH probe, Vysis, USA) as reported previously.[@b9-cin-11-2012-173] All Ph(+)ALL and 5 out 10 CML blast crisis samples had established B cell immunophenotype.[@b6-cin-11-2012-173],[@b10-cin-11-2012-173]

Having identified genome regions of potential interest, ranked in order of significance, out of the thousands of array results, it is then a challenge to design further experiments to evaluate their contribution to the biology of the BCR/ABL positive disease.

Materials and Methods
=====================

Array CGH analysis was performed as described previously.[@b6-cin-11-2012-173] Briefly, Agilent (Wilmington, DE, USA) oligonucleotide arrays were hybridized following the manufacturer's protocol. 500 ng genomic test DNA was extracted from either peripheral blood or BM samples. Sex mismatched pooled DNA from peripheral blood mononuclear fraction of 6--8 disease free individuals (Promega, UK) was used as reference. Customized Agilent oligonucleotide arrays comprising 8 × 15 k probe sets per slide were designed from an analysis of active loci (hot spots) in the CML BC genome corresponding to pairs of probes that exceeded a 3SD threshold in 3 or more CML BC samples from a previous study.[@b5-cin-11-2012-173] Probes were selected to cover regions at \~1 k intervals except where the presence of repetitive sequences disallowed the inclusion of reliable probes.

The arrays were scanned, features extracted and the data analyzed using an Agilent scanner and Mathematica software (<http://www.wolfram.com>). In addition, all samples had been subjected to whole genome screening using 105 K Agilent oligonucleotide arrays as part of published study.[@b6-cin-11-2012-173]

The emergence of high throughput technology such as microarrays raises a fundamental statistical issue relating to testing hundreds of hypotheses thus rendering the standard *P* value meaningless.[@b11-cin-11-2012-173] The False Discovery Rate (FDR) concept is an alternative to the *P* value. Tusher[@b1-cin-11-2012-173] described such a method: Significance Analysis of Microarrays (SAM) and the implementation due to Chu et al has been incorporated by J Craig Venter Institute into their suite of 'MeV' routines.[@b12-cin-11-2012-173] SAM uses permutations of sample labels to estimate the FDR. We report the application of SAM for 5,000 permutations setting the median number of false significant probes to zero, for the supervised analysis of the myeloid and lymphoid blast crisis, chronic CML, Ph(+)ALL and control samples. Firstly, after removing data for the sex chromosomes, we constructed a table defining the log fluorescence ratio (FR) for each locus and assigned classes eg, Lymphoid blast phase CML (L) or Myeloid blast phase CML (M); Ph(+)ALL (ALL); Chronic phase CML (C); Control (Ctrl); Male (m) or Female (f). We chose a two class unpaired test and applied SAM to ask if there were any probes that were uniquely associated with either classification. All genome addresses are derived from build 35 (March 2006) of the Human Genome.

Results
=======

Genomic difference between lymphoid and myeloid lineages
--------------------------------------------------------

We applied SAM to seek correlations between genome imbalances and clinical presentation. We asked which probes were significantly involved in the discrimination between lymphoid and myeloid lineages using the classes of myeloid and lymphoid CML BC as a model. Altogether we identified 489 significant probes, the top 100 of which were restricted to the TCR, IKZF1 and IgH genomic regions. [Figure 1](#f1-cin-11-2012-173){ref-type="fig"} shows cluster analysis of the 40 most significant probes indicating losses occurring at genome address between 105,405,310 and 105,518,122 mbp in the IgH region, between 38,287,976 and 38,315,044 mbp in TCR and between 50,385,101 and 50,429,250 mbp in the sequences of IKZF1 ([Table 2](#t2-cin-11-2012-173){ref-type="table"}). Lymphoid samples including Ph(+)ALL clustered together displaying losses ([Fig. 1](#f1-cin-11-2012-173){ref-type="fig"} on the left), while the myeloid blast crisis and chronic CML samples formed a separate cluster with the control samples ([Fig. 1](#f1-cin-11-2012-173){ref-type="fig"} on the right). We noted that 3 samples sat at the myeloid/lymphoid borderline and that some of the control samples showed losses in the TCR region.

Comparison of CML lymphoid blast crisis and Ph(+)ALL
----------------------------------------------------

84% of the 155 probes differentiating lymphoid blast crisis CML and Ph(+)ALL map to one of two regions of the short arm of chromosome 9, namely 9p21.3--p21.2 and 9p24.1--p23, the latter housing genes PTPRD and MLLT3 among others. A hierarchical cluster analysis shows that five of the 10 Ph(+)ALL cases form a cluster of gains ([Fig. 2](#f2-cin-11-2012-173){ref-type="fig"}, in red) although cytogenetic revealed no structural or numerical changes of 9p ([Table 1](#t1-cin-11-2012-173){ref-type="table"}). In contrast, half of the 10 CML BCL cases formed a cluster with extensive genome loss (in green) that had been previously shown to be complex by G-banding and 105 K oligonucleotide array.[@b6-cin-11-2012-173] See [Figure 2](#f2-cin-11-2012-173){ref-type="fig"} and [Table 3](#t3-cin-11-2012-173){ref-type="table"}.

Since many of the significant probes fell on chromosome 9p we repeated the analysis excluding all chromosome 9 loci. The top 10 of 80 probes meeting our significance threshold are revealed by cluster analysis (see [Fig. 3](#f3-cin-11-2012-173){ref-type="fig"} and [Table 4](#t4-cin-11-2012-173){ref-type="table"}). Associated with these loci are known genes s uch as PDEA4 (cAMP-diestarase) in band 19p13.2 and GSTT1 in band 22q11.23, one of the most commonly reported polymorphic marker (CNV) in man. Genome loss (in green, [Fig. 3](#f3-cin-11-2012-173){ref-type="fig"}) dominates the profile of 6 out 10 Ph(+)ALL samples. Surprisingly 5 of the latter cases (297, 299, 300, 301, 303) exhibit gains in the chromosome 9p21--p24 region ([Fig. 3](#f3-cin-11-2012-173){ref-type="fig"}, heat map A).

It is suggested from the heat maps in [Figures 2](#f2-cin-11-2012-173){ref-type="fig"} and [3](#f3-cin-11-2012-173){ref-type="fig"} that the Ph(+)ALL samples split into two groups, 5/10 cases showing dominant amplification of loci in the chromosome 9p region and losses elsewhere in the genome, while the remainder (5/10) lack recurrent genome imbalances. However, we were unable to detect any consistent differences in the two groups of Ph(+)ALL samples from an inspection of their chromosome status (see [Table 1](#t1-cin-11-2012-173){ref-type="table"}).

In summary, SAM analysis revealed that while the lymphoid blast stage CML and Ph(+)ALL samples share common losses within the IGH, TCR, and *Ikaros* gene regions together with loci within the 9p21--p24 region, they form separate clusters at other sites on the genome thus suggesting that these acute malignant conditions may represent separate biological entities.

Discussion
==========

Whilst huge progress has been made in the analysis of the genome and the identification of genes associated with malignant disease, there is still much work to be done evaluating the function of coding and noncoding regions[@b13-cin-11-2012-173]. We have identified numerous short 60 mer sequences that appear to play a significant role in the evolution of Philadelphia positive hematological malignancy. We offer no explanation of their function, but provide convincing evidence that their involvement is not a random event.

SAM is used for the analysis of expression arrays to classify samples into groups according to phenotype using false discovery rate (FDR) as a test for significance.[@b1-cin-11-2012-173],[@b14-cin-11-2012-173] Here we use SAM to study DNA from a cohort of CML and Ph(+)ALL patients to identify sequences that may help to distinguish between these Philadelphia positive diseases and enlighten their pathogenesis.

Numerous software packages are available for the detection of genomic gains and losses across a range of array technologies, reviewed by Shah,[@b15-cin-11-2012-173] but high-resolution array data presents special problems as typified by a wide variance making detection of small features complicated. Individual signals are rarely if ever considered to be significant on their own but only in the context of a contiguous collections of gains and losses. However if an individual locus is compared across a number of similarly processed arrays, the probability of a random single signal exceeding a 3SD threshold for ***n*** arrays is reduced to approximately (0.003)\^**n**. FR signals meeting these criteria could be attributable to artifacts of the array and laboratory procedures or could be *bona fide* data with clinical significance. Since all the samples in our study were prepared under the same conditions and hybridized to the same batch of arrays, we believe that the results reflect recurrent genome copy number aberrations. Our data shows consistent, recurrent gains and losses although in many cases the FR data falls well short of the theoretical values suggesting the presence of clonal cell populations---a common phenomenon in haematological disease. SAM does not guarantee that the list of 'significant' loci are involved in the various classifications discussed here, but it does offer a list of candidates for cluster analysis or other investigative methods. Many gene copy number changes irrespective of the length of the affecting sequences such as those recorded here can contribute directly to monogenic diseases[@b16-cin-11-2012-173]. In recessive diseases, hemizygosity due to deletion of a gene, or part of a gene, could unmask a mutation on the other gene copy, while duplication of a healthy gene copy on one chromosome could theoretically mask the effects of a disease- causing mutation in the gene on the other chromosome, thus rescuing the phenotype.

We designed a high resolution array (\~1 kb intervals) designed to explore regions of the genome shown previously at low (33 kb) resolution to display gains or losses in a cohort of 35 samples from CML patients in blast phase[@b6-cin-11-2012-173]. This necessitated sacrificing large areas of the genome to concentrate on these areas for detailed inspection. Using this set of \~15,000 genetic loci enabled us to confirm that lymphoid phenotypes formed a single group characterized primarily by unique deletions within the IgH regions consistent with an early VDJ rearrangement as part of the B cell receptor formation occurring in per-B cells together with loss of the TCR gamma sequences also indicating gene rearrangement. Loss of whole or part of the IKZF1 (*Ikaros*) gene is the third most common feature in the genome profile of these cases. In contrast with a typical CNV that could affect any part of the IgH gene on 14q32.33 the deletions identified by us always involve the sequences 105.41--105.48 mbp and are almost universally accompanied by deletions in the TCR region of chromosome 7. Both IgH and TCR sequences are usually excluded from aCGH analysis as they are reported to be CNVs. We have demonstrated that these deletions are consistent throughout the sample set, suggesting that they are disease specific. These findings could be explained by a chain of events initiated by *BCR*/*ABL1* that leads to compromised V(D)J recombinase machinery thus creating clonal populations of early B-cell progenitors with cross lineage rearrangements.[@b6-cin-11-2012-173] Mullighan et al in their poster presentation "Genome wide analysis of Genetic Aberrations in Chronic Myeloid Leukemia" (Mullighan et al, <http://ash.confex.com/ash/2008/webprogram/Paper5715.html>) reported results from SNP analysis of 90 CML samples of which 9 were diagnosed as lymphoid blast crisis. This study could not find any genomic features that could differentiate between BC/L and Ph(+)ALL. In contrast we were able to reveal genomic differences in these clinically similar conditions.

Many of the 'significant' probes that distinguish between Ph(+)ALL and BC/L cluster within chromosome 9p21 region, which harbours the CDKN2A/B gene, the loss of which has long been associated with both haematological and solid tumours and shown to result from RAG impairment.[@b8-cin-11-2012-173] to carry imbalances of the short arm of chromosome 9, it is possible that some probes in this location were lost 'by association' and not involved in discriminating between these two diseases. However, we found other loci that did discriminate between Ph(+)ALL and BC/L CML. For example, while half of the BC/L cases had deletions in chromosome 9p, half of the of Ph(+)ALL showed gains at these loci as shown in [Figure 2](#f2-cin-11-2012-173){ref-type="fig"}. Omitting chromosome 9 records and reanalyzing the data, the same five Ph(+)ALL samples showed significant losses in 80 loci from other chromosomal locations ([Fig. 3](#f3-cin-11-2012-173){ref-type="fig"}). Taken together the tandem CNA---gains at 9p with recurrent losses elsewhere in the genome offer a way to differentiate a Ph(+)ALL from CML lymphoid BC. Whilst we recognize that single aberrant 60 mer sequences could easily be dismissed as random events, the fact that there are more than 80 widely distributed probes not associated with morphological or cytogenetic anomalies but associated with a significant minority of the Ph(+)ALL samples is worth consideration. Further work is required to explore the possible role of these genome aberrations. In conclusion, SAM results offer clues regarding the pathogenesis of *BCR*/ *ABL1* positive disorders and furthermore identifies a sets of probes with diagnostic potential.
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![Top 40 most significant probes from a cluster analysis of 489, distinguishing lymphoid and myeloid BCR/ABL1 positive genomes.\
**Notes:** SAM analysis listed a total of 489 significant probes that discriminate between lymphoid and myeloid BCR/ABL1 positive genomes. The top 20% of these probes were associated with the TCR \@chr7:38,287,976-38,315,044 and the IgH region \@chr14:105,405,310-105,518,122. Arrow points to homozygous deletions of the IgH probes (bright green) seen exclusively in Ph(+) samples with an early B cell lymphoid phenotype.](cin-11-2012-173f1){#f1-cin-11-2012-173}

![Identification of probes discriminating between ph positive acute lymphoblastic leukemia and CML lymphoid blast transfomation.\
**Notes:** Heat map of the SAM data showing gains (red) and losses (green) for the 40 probes most influential in discriminating between Ph(+)ALL and BC/L CML samples. Altogether 16 of these probes (arrowed) cover the region of the PTPRD gene (protein tyrosine phosphatase, receptor type, D) on 9p24.1--p23. A sub group of 5 Ph(+)ALL samples show gains of chromosome 9p loci (red arrow), whilst the same region in 5 BC/L CML samples is deleted (green arrow) in agreement with their chromosome status.](cin-11-2012-173f2){#f2-cin-11-2012-173}

![Ph positive all with gains at 9p21--p24 share common losses elsewhere in the genome.\
**Notes:** Cluster analysis of SAM data identified cryptic gains within the 9p21--p24 region in a sub-group of Ph(+)ALL samples (framed in heat map A, losses in green and gains in red). When cluster analysis was performed on SAM results of the genome excluding chromosome 9 data, some 115 probes were shown to discriminate between Ph(+)ALL and BCL CML, the top 10 of which are shown on the heat map B (losses in green and gains in red). All but one (arrowed) of these Ph(+)ALL samples with gains in the 9p21--p24 region share cryptic loss elsewhere in the genome (framed, heat map B), which involves relevant genes such as CYP11B2 (cytochrome P450), GCSTT1 (member of the glutathione transferase gene family with known role in carcinogenesis) and CHAF1A (chromatin assembly factor) among others.](cin-11-2012-173f3){#f3-cin-11-2012-173}

###### 

Summary of chromosome and fish results for the Ph(+)ALL cases.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No   Case ID       Karyotype                                                                               BCR breakpoint   FISH [\*](#tfn2-cin-11-2012-173){ref-type="table-fn"} BCR/ABL1   FISH[\*](#tfn2-cin-11-2012-173){ref-type="table-fn"} *p16*   FISH[\*\*](#tfn3-cin-11-2012-173){ref-type="table-fn"} *Ikaros*   FISH[\*\*](#tfn3-cin-11-2012-173){ref-type="table-fn"} *PAX*5   FISH[\*\*](#tfn3-cin-11-2012-173){ref-type="table-fn"} Fusion                                                               
  ---- ------------- --------------------------------------------------------------------------------------- ---------------- ---------------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------- ---------
  1    296/165       46,XX,t(9;22)(q34;q11)\[11\]/46,idem,der(5)t(1;5)(q2;q2)\[8\]/46,XX\[3\]                m-BRC            Yes                                                              No                                                           No                                                                Loss                                                            Loss                                                            ND                                                          ND

  2    297/139/267   46,XY,t(9;22)(q34;q11)\[10\]                                                            m-BCR            Yes                                                              No                                                           No                                                                Diploid                                                         Diploid                                                         ND                                                          Diploid

  3    298/140       46,XY \[10\]                                                                            m-BRC            Yes                                                              No                                                           Yes*[\*\*\*](#tfn4-cin-11-2012-173){ref-type="table-fn"}*         No                                                              ND                                                              ND                                                          ND

  4    299/136       57,XY,+X,+Y,+2,add(2)(p?),+4,+8, t(9;22)(q34;q11),+10,+13,+14,+1\                       m-BRC            Yes                                                              Yes                                                          Yes*[\*\*\*](#tfn4-cin-11-2012-173){ref-type="table-fn"}*         Yes*[\*\*\*](#tfn4-cin-11-2012-173){ref-type="table-fn"}*       Yes*[\*\*\*](#tfn4-cin-11-2012-173){ref-type="table-fn"}*       No                                                          ND
                     5,+21,+der(22)t(9;22)\[4\]/ 57,idem,add(2)(p?),+del(2)(p11),+ 11,−15\[3\]/ 46,XY\[5\]                                                                                                                                                                                                                                                                                                                                                                                                                

  5    300/166       46,XY,t(9;22)(q34;q11)\[10\]                                                            m-BRC            Yes                                                              No                                                           Yes*[\*\*\*](#tfn4-cin-11-2012-173){ref-type="table-fn"}*         No                                                              Yes*[\*\*\*](#tfn4-cin-11-2012-173){ref-type="table-fn"}*       Yes*[\*\*\*](#tfn4-cin-11-2012-173){ref-type="table-fn"}*   ND

  6    301/142       46,XY,t(9;22)(q34;q11.2)\[9\]/ 46,XY\[1\]                                               m-BRC            Yes                                                              No                                                           No                                                                No                                                              No                                                              No                                                          ND

  7    302/170       46,XX,t(9;22;17)(q34;q11;q21)\[1\]/48,idem,+X,+14\[7\]/46,XX\[4\]                       m-BRC            Yes                                                              No                                                           No                                                                ND                                                              ND                                                              ND                                                          ND

  8    303/131       52,XY,+X,+4,+5,+7,+8, t(9;22)(q34;q11),+20\[6\]/ 46,XY\[4\]                             m-BRC            Yes                                                              No                                                           No                                                                ND                                                              ND                                                              ND                                                          ND

  9    304/138       46,XY,t(9;22)(q34;q11)\[7\]/ 46,XY\[3\]                                                 m-BRC            Yes                                                              No                                                           Yes[\*\*](#tfn3-cin-11-2012-173){ref-type="table-fn"}             No                                                              Yes[\*\*](#tfn3-cin-11-2012-173){ref-type="table-fn"}           ND                                                          ND

  10   305/130/269   46,XY,t(9;22)(q34;q11)\[20\]                                                            m-BRC            Yes                                                              No                                                           No                                                                ND                                                              ND                                                              ND                                                          ND
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

D-FISH using commercial probes (Vysis);

using customised dual colour/dual probes (BAC and/or fosmid);

cryptic loss identified only by high resolution array CGH.

**Abbreviations:** m-BCR, minor breakpoint; M-BCR, major breakpoint; ND, not done.

###### 

The 40 most significant probes differentiating between lymphoid and myeloid lineages.

  Probe            Chr   Target                       Address mbp   Expected score   Observed score
  ---------------- ----- ---------------------------- ------------- ---------------- ----------------
  A_18_P20213662   14    chr14:105414227--105414286   105.414227    −0.563993        −7.793448
  A_18_P12135242   14    chr14:105413378--105413437   105.413378    −0.56458443      −7.7092276
  A_16_P02991277   14    chr14:105422205--105422249   105.422205    −0.5605237       −7.3922744
  A_16_P20175261   14    chr14:105426753--105426797   105.426753    −0.5587666       −7.2691813
  A_18_P20215586   14    chr14:105422720--105422764   105.42272     −0.5601302       −7.137599
  A_16_P02991277   14    chr14:105422205--105422249   105.422205    −0.56032795      −7.105713
  A_16_P20175223   14    chr14:105416396--105416455   105.416396    −0.5630354       −6.8957753
  A_16_P20175218   14    chr14:105414975--105415034   105.414975    −0.5638017       −6.803494
  A_16_P40322315   14    chr14:105413708--105413767   105.413708    −0.5643853       −6.7806916
  A_16_P20175223   14    chr14:105416396--105416455   105.416396    −0.56323034      −6.704411
  A_16_P40322315   14    chr14:105413708--105413767   105.413708    −0.5641888       −6.6329618
  A_18_P12136981   14    chr14:105422914--105422973   105.422914    −0.5599273       −6.6110125
  A_16_P20175222   14    chr14:105416160--105416219   105.41616     −0.5634191       −6.426458
  A_16_P01695449   7     chr7:38297984--38298042      38.297984     0.12489289       −6.2314205
  A_16_P40322466   14    chr14:105455799--105455843   105.455799    −0.5500808       −6.107134
  A_16_P17913603   7     chr7:38310399--38310458      38.310399     0.12737036       −6.08846
  A_16_P37994547   7     chr7:38298861--38298920      38.298861     0.1250429        −6.059183
  A_16_P02991291   14    chr14:105434927--105434971   105.434927    −0.5564316       −6.0575943
  A_16_P40322313   14    chr14:105406766--105406825   105.406766    −0.56478184      −6.0261383
  A_18_P12135286   14    chr14:105444052--105444096   105.444052    −0.5535429       −5.963885
  A_16_P17913579   7     chr7:38302124--38302183      38.302124     0.1256673        −5.9104414
  A_16_P37994526   7     chr7:38291724--38291783      38.291724     0.12381547       −5.8998003
  A_18_P25472429   7     chr7:38303632--38303691      38.303632     0.12597458       −5.8726745
  A_16_P02991281   14    chr14:105426482--105426526   105.426482    −0.55895203      −5.8314695
  A_16_P02991264   14    chr14:105405952--105406011   105.405952    −0.5651721       −5.7746663
  A_16_P17913610   7     chr7:38312900--38312959      38.3129       0.12768513       −5.768144
  A_16_P02991284   14    chr14:105427876--105427920   105.427876    −0.5581815       −5.7465305
  A_16_P40322308   14    chr14:105405310--105405355   105.40531     −0.56556815      −5.698316
  A_16_P17913618   7     chr7:38315044--38315103      38.315044     0.12799555       −5.660891
  A_16_P17941758   7     IKZF1                        50.397299     0.1786682        −5.6329775
  A_16_P17913559   7     chr7:38295440--38295499      38.29544      0.12458947       −5.617972
  A_16_P02991279   14    chr14:105425440--105425486   105.42544     −0.5593441       −5.6175857
  A_16_P01711866   7     IKZF1                        50.385101     0.17555533       −5.6086626
  A_16_P17941722   7     IKZF1                        50.387437     0.17618023       −5.5908685
  A_16_P02991264   14    chr14:105405952--105406011   105.405952    −0.5649764       −5.544837
  A_18_P12136727   14    chr14:105451511--105451559   105.451511    −0.5502752       −5.5420628
  A_18_P20215609   14    chr14:105518122--105518166   105.518122    −0.539346        −5.5144167
  A_16_P01695465   7     chr7:38305379--38305438      38.305379     0.1264447        −5.477569
  A_18_P16088644   7     IKZF1                        50.42925      0.18619013       −5.435862
  A_16_P37994528   7     chr7:38292369--38292428      38.292369     0.12397207       −5.42713

**Notes:** The differential (Expected---Observed) is a measure of significance.

###### 

The 40 most significant probes differentiating between Ph(+)ALL and lymphoid blast crisis.

  Probe            Chr   Target                      Address mbp   Expected score   Observed score
  ---------------- ----- --------------------------- ------------- ---------------- ----------------
  A_16_P18581907   9     chr9:23573321-- 23573380    23.573321     1.217212         −5.9455347
  A_18_P26464352   9     chr9:23606102-- 23606161    23.606102     1.2239254        −5.305494
  A_16_P02074143   9     MLLT3                       20.358557     0.870436         −4.711568
  A_14_P136633     13    TRPC4                       37.12336      −0.8066902       −4.5697494
  A_16_P02056848   9     PTPRD                       8.670463      0.69564855       −4.4780617
  A_18_P16772095   9     chr9:20235638-- 20235697    20.235638     0.8584173        −4.453213
  A_16_P18547080   9     PTPRD                       9.114454      0.7288707        −4.4257317
  A_18_P26401468   9     chr9:7431806-- 7431865      7.431806      0.6581821        −4.364759
  A_16_P18582203   9     chr9:23668631-- 23668690    23.668631     1.2362497        −4.320358
  A_16_P18581984   9     chr9:23597611-- 23597670    23.597611     1.2221186        −4.288423
  A_16_P18546259   9     PTPRD                       8.8232        0.70854175       −4.271888
  A_16_P18581300   9     chr9:23307181-- 23307240    23.307181     1.178406         −4.268987
  A_16_P18590554   9     chr9:27291345-- 27291404    27.291345     1.2408848        −4.2311144
  A_16_P18542386   9     chr9:7348833-- 7348892      7.348833      0.6530274        −4.1917768
  A_18_P16743757   9     PTPRD                       9.54851       0.7599531        −4.189755
  A_16_P38678778   9     chr9:23377660-- 23377719    23.37766      1.1883749        −4.1894665
  A_16_P38644284   9     PTPRD                       9.261361      0.73997337       −4.1806855
  A_16_P18545920   9     PTPRD                       8.706239      0.69865716       −4.108792
  A_16_P38647612   9     PTPRD                       10.509098     0.83521545       −4.095142
  A_16_P38643011   9     PTPRD                       8.791208      0.70617497       −4.092501
  A_16_P02078229   9     chr9:23405562-- 23405621    23.405562     1.1912949        −4.0642586
  A_16_P18548249   9     PTPRD                       9.557477      0.7608688        −4.042481
  A_18_P16749071   9     PTPRD                       10.587629     0.8423635        −4.0077705
  A_16_P02096462   9     PAX5                        36.886181     1.439173         −3.9982088
  A_16_P02078274   9     chr9:23432592-- 23432651    23.432592     1.1954948        −3.9890935
  A_16_P18579921   9     chr9:22668742-- 22668801    22.668742     1.1000694        −3.9809976
  A_16_P19916466   13    GPC6                        93.756923     −0.729778        −3.9487815
  A_16_P18551018   9     PTPRD                       10.585886     0.8421173        −3.9478562
  A_16_P18581339   9     chr9:23328196-- 23328255    23.328196     1.1817318        −3.9457936
  A_16_P38679470   9     chr9:23641904-- 23641963    23.641904     1.2316526        −3.9433708
  A_16_P02077983   9     chr9:23212115-- 23212174    23.212115     1.1630332        −3.937294
  A_16_P18582128   9     chr9:23645570-- 23645629    23.64557      1.232107         −3.927982
  A_16_P38642152   9     PTPRD                       8.516555      0.68393993       −3.9103673
  A_16_P19909107   13    GPC5                        91.029609     −0.735624        −3.8958812
  A_16_P38645300   9     PTPRD                       9.629695      0.7672258        −3.861492
  A_16_P02822684   13    chr13:82376752-- 82376811   82.376752     −0.74305904      −3.8531454
  A_16_P38641641   9     PTPRD                       8.373899      0.6731849        −3.8528354
  A_16_P18542873   9     chr9:7534498-- 7534557      7.534498      0.66606975       −3.847243
  A_16_P18550697   9     PTPRD                       10.463268     0.832524         −3.8354936
  A_18_P16742333   9     PTPRD                       10.444266     0.83104974       −3.278083

**Notes:** The differential (Expected---Observed) is a measure of significance.

###### 

The 40 most significant probes differentiating between Ph(+)ALL and lymphoid blast crisis excluding chromosome 9 probes.

  Probe            Chr   Target                       Address mbp   Expected score   Observed score
  ---------------- ----- ---------------------------- ------------- ---------------- ----------------
  A_16_P02042251   8     CYP11B2                      143.994134    −0.49485415      −3.6447732
  A_16_P02984473   14    chr14:100110458--100110502   100.110458    −0.3787858       −3.4324715
  A_18_P12974340   19    CHAF1A                       4.361883      0.73060995       −3.3821597
  A_16_P41139830   19    PDE4A                        10.4373       0.588393         −3.3786511
  A_16_P02992588   15    chr15:19466732--19466791     19.466732     −0.3425412       −3.357904
  A_14_P127778     13    chr13:104954398--104954457   104.954398    −1.219279        −3.2696884
  A_18_P12746992   17    DNAH17                       73.949223     0.72273785       −3.236283
  A_16_P20748371   17    chr17:78157979--78158038     78.157979     0.23752803       −3.197567
  A_16_P41491725   22    GSTT1                        22.713973     0.59368485       −3.112421
  A_16_P03295625   17    DNAH17                       73.998258     −0.27195758      −3.1080885
  A_18_P20749354   16    chr16:88235603--88235662     88.235603     1.1027136        −3.094033
  A_16_P40556488   16    chr16:10502024--10502083     10.502024     0.5570203        −3.0405986
  A_16_P20957257   19    PDE4A                        10.434299     0.2495674        −3.021277
  A_16_P02380585   11    chr11:1822652--1822711       1.822652      −0.4423064       −2.9679623
  A_16_P03204073   17    P2RX5                        3.525384      −0.3101799       −2.9653873
  A_16_P03605977   22    GSTT1                        22.710302     −0.22612213      −2.9506812
  A_16_P20690191   17    GDPD1                        54.658506     0.22053438       −2.9496646
  A_16_P20568636   17    chr17:3283949--3284008       3.283949      0.19664884       −2.8752325
  A_14_P132357     17    38595                        72.827808     −1.1807562       −2.8733869
  A_16_P02738683   13    SPATA13                      23.761279     −0.41567326      −2.8507361
  A_18_P10967751   11    chr11:1252096--1252155       1.252096      0.63722944       −2.8453183
  A_16_P03601865   22    RANBP1                       18.494441     −0.23352942      −2.8380888
  A_16_P35654245   2     MTA3                         42.787245     0.34639606       −2.8232927
  A_16_P17507488   6     chr6:35880489--35880548      35.880489     −0.12230495      −2.8113792
  A_16_P39158050   10    CNNM2                        104.799592    0.49181423       −2.798708
  A_16_P39157984   10    CNNM2                        104.769703    0.49056116       −2.7931175
  A_18_P20982233   17    chr17:72013234--72013278     72.013234     1.128489         −2.7917495
  A_16_P19045973   10    CNNM2                        104.701305    0.07244033       −2.7840393
  A_18_P12745203   17    DNAH17                       73.995598     0.72024244       −2.7796998
  A_16_P15021468   1     RERE                         8.650802      −0.21963291      −2.7703693
  A_16_P02991501   14    chr14:105737025--105737080   105.737025    −0.35576868      −2.7698457
  A_16_P01729453   7     CALN1                        71.497024     −0.6459507       −2.767063
  A_16_P35654127   2     MTA3                         42.736918     0.34621632       −2.7501495
  A_14_P120530     21    AIRE                         44.541215     −1.3012085       −2.7431655
  A_18_P12659257   17    KIAA1267                     41.493236     0.70809025       −2.7361684
  A_16_P02873949   14    chr14:22054604--22054663     22.054604     −0.38419548      −2.7211492
  A_16_P20660234   17    NSF                          42.162        0.21277878       −2.7152972
  A_16_P03422686   19    chr19:10389923--10389975     10.389923     −0.24484406      −2.7065868
  A_16_P19930395   13    chr13:99371784--99371843     99.371784     0.1376494        −2.7023811
  A_16_P40862888   17    GDPD1                        54.689835     0.5801528        −2.6963766

**Notes:** The differential (Expected---Observed) is a measure of significance.
